UPB (Upstream Bio) Change In Receivables : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio Change In Receivables?

Upstream Bio's change in receivables for the quarter that ended in Dec. 2024 was $0.00 Mil. It means Upstream Bio's Accounts Receivable stayed the same from Sep. 2024 to Dec. 2024 .

Upstream Bio's change in receivables for the fiscal year that ended in Dec. 2024 was $-0.52 Mil. It means Upstream Bio's Accounts Receivable increased by $0.52 Mil from Dec. 2023 to Dec. 2024 .

Upstream Bio's Accounts Receivable for the quarter that ended in Dec. 2024 was $0.61 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Upstream Bio's Days Sales Outstanding for the three months ended in Dec. 2024 was 91.25.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Upstream Bio's liquidation value for the three months ended in Dec. 2024 was $459.04 Mil.

Upstream Bio Change In Receivables Historical Data

The historical data trend for Upstream Bio's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio Change In Receivables Chart

Upstream Bio Annual Data

Trend

Dec22

Dec23

Dec24

Change In Receivables

-0.41

0.31

-0.52

Upstream Bio Quarterly Data
	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial			-	-	-	-	-

Upstream Bio Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Upstream Bio (NAS:UPB) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Upstream Bio's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.613	/	0.613	*	91
=	91.25

2. In Ben Graham's calculation of liquidation value, Upstream Bio's accounts receivable are only considered to be worth 75% of book value:

Upstream Bio's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	470.451	-	11.867	+	0.75 * 0.613	+	0.5 * 0
=	459.04

Upstream Bio Change In Receivables Related Terms

Thank you for viewing the detailed overview of Upstream Bio's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Upstream Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

890 Winter Street, Suite 200, Waltham, MA, USA, 02451

Website

https://www.upstreambio.com

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.